The Vanguard Group's Stake in Avadel Pharmaceuticals

The Vanguard Group, Inc. has disclosed its position concerning Avadel Pharmaceuticals plc under the Irish Takeover Panel's Form 8.3. The disclosure was made on December 2, 2025, showing Vanguard's ownership of 5,582,423 ordinary shares, equivalent to 5.73% of the company's securities.

This form details the interests and short positions Vanguard holds in Avadel Pharmaceuticals' securities. The shares are priced at $0.01 each. The filing also includes purchase and sale activities, noting the purchase of 784 shares and the sale of 138 shares, both at a rate of $21.35 per share.

No cash-settled or stock-settled derivatives transactions were listed, and The Vanguard Group reported no indemnity or option arrangements connected to these securities. There are also no agreements concerning voting rights or future transactions involving Avadel's securities.